Incidence of type II diabetes mellitus among patients with chronic myelogenous leukemia (CML) receiving first or second line therapy with dasatinib or nilotinib.

The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective

“…Treatment with nilotinib was associated with a worsening of the glycometabolic profile compared to patients treated with dasatinib and imatinib [37]. Further, claims data analysis from U.S. commercial and Medicare payers indicated that patients receiving nilotinib, either as first-or second-line therapy, had a higher risk of developing metabolic diseases like Type 2 diabetes mellitus [38] and hyperlipidemia [39] compared to those on dasatinib. Based on the differences in the safety profiles, the NCCN guidelines recommend consideration of certain comorbidities including heart disease, arrhythmia, diabetes, pancreatitis, pleural effusion, and lung disease while making treatment decisions related to 2G TKIs [3].…”